| 摘要 |
<p>A method of using a surrogate, preferably 99mTc-MDP, for a therapeutic agent (for example, 166Ho-EDTMP or preferably 166Ho-DOTMP) to calculate the dosimetry for the therapeutic dose for bone marrow ablation therapy is disclosed. The advantages of this use of a surrogate in lieu of the therapeutic agent is lower cost, less exposure to high radiation levels, and length of the half-life, while maintaining the biodistribution in the total skeleton.</p> |
